Audit: QRS - Shabad Kriya for Health & Longevity
Audit conducted on 02/09/2026 01:34 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 86 |
| Failed | 0 |
| N/A | 7 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked against the ER: protocol cells vs ER Therapeutic Protocol (lines 327-337), gates vs Key Interactions & Contraindications (lines 271-299), tiers vs the Expected Benefits / Potential Risks & Side Effects headings, monitoring vs the ER biomarker table (lines 410-420). No unsupported statement found. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious phrasing carried through: marker_6_target keeps “No established target”; time_2_sub keeps “Adherence beyond that was never recorded” (ER line 354). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening detected; contraindication thresholds (>=180/110 mmHg, <90 days, 12 months, 15/hour) are reproduced at ER severity. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come from the ER “Populations who should avoid Shabad Kriya” list, interactions from the interaction bullets, tiers from the benefit/risk headings. No Benefit- or Risk-Modifying Factor is surfaced as a caution or side effect. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, investigator names, study years or brand names appear anywhere in the QRS body. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No new attributions; at_a_glance refers to “one researcher with a stake in the practice” without naming, matching the ER Conclusion (line 452). |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Tone matches the ER: sober, hedged where the ER hedges, plain-spoken about the single-investigator evidence base. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven (thresholds, tiers, cadence) while remaining accessible; the free, zero-equipment framing is empowering. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence and thresholds rather than prescribing; no directive verbs addressed to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No clinical advice; the footer disclaimer is the fixed template text. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Information is presented, not recommended; time_3_sub uses the ER nominalisation “escalation to cognitive behavioral therapy for insomnia”. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person forms anywhere in the QRS body (scanned for “you”, “your”, “yourself”, “we”, “our”, “us” - zero hits). |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language throughout; clinical terms carry the ER glosses (“myocardial infarction (heart attack…)”, “unstable angina (chest pain at rest)”). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every element is condensed: tiers to one line each, interactions to label plus classification, protocol to three cells. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by the same second-person scan as 2.6; the document never addresses the reader. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing suits proactive, risk-aware adults: an 11-31 minute nightly commitment, an 11-marker panel and a wearable-based baseline. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Assumes willingness to run a 14-night baseline, an eight-week evaluation and a nightly seated practice. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not pitched at the general population; the monitoring and decision-point content presupposes deliberate self-experimentation. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Risk/benefit weighting reflects the audience: the single-investigator limitation and the “everything beyond sleep is borrowed” caveat are surfaced up front. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not appear; aging content is framed as “slower cellular aging markers”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terminology used (“sedative-hypnotics”, “myocardial infarction”, “antihypertensives”); the plain-language glosses are the ER’s own. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings match the template: Protocol, Time to effect, Benefits, Risk & Side Effects, Monitoring, Qualitative Assessment, Contraindications, Key Interactions, the four tier labels and Marker/Target/Why. |
| 3.2 | All “<span data-qrs-var=”NAME”>…</span>” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template variable names are present; marker_#* and qualitative_item# are expanded to marker_1..11 and qualitative_item_1..7. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Structural diff against the template shows changes only inside checklist-addressed spans; the website=”evidence_review”, website=”audit” and website=”full_review” spans, the CSS and the footer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | 🟢 | No ER section mapped to the QRS is empty; the two absent tiers are handled by 12.5/13.5 (display:none) rather than empty-state text. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels are the ER bold labels verbatim (“Breath ratio”, “Duration”, “Best time of day”); monitoring row labels are the ER biomarker names verbatim; interaction labels keep the ER head noun verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No invented labels in the bullet-derived rows; the Time-to-Effect cell labels are section-level syntheses rather than transcriptions of a single ER bold label. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji anywhere in the file; tiering is conveyed by bold labels and CSS colour only. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section the checklist permits to be condensed is condensed to a single line or cell per tier/aspect; the fully enumerated sections (11 biomarkers, 7 qualitative markers, 7 contraindications, 10 interactions) are mandated complete by 14.2, 15.2, 8.2 and 9.2. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment opens at line 2, immediately after “<!doctype html>” on line 1, before any other comment, head or body content. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML opens with “—” at line 3 and closes with “—” at line 13; the preceding title text sits before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Wrapped in an HTML comment, so it does not render and is not echoed by any element on the sheet. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration: “00:04” is quoted, which is required because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: shabad_kriya_2026-0902-0011_Opus_ER.md, which is the source ER on disk. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0902-0127, in YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: shabad_kriya_2026-0902-0011_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified: no stray whitespace and no unnecessary quoting in any of the nine frontmatter values. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Title is “Shabad Kriya for Health & Longevity - Quick Reference Sheet”; the canonical_topic is entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | header_topic is “Shabad Kriya for Health & Longevity”, the ER canonical_topic entity-encoded. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | header_subline_date is 09/02/2026, the MM/DD/YYYY form of qrs_creation_date 2026-0902-0127. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | header_subline_model is “Opus 5”, matching qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the title and the fixed subline; no badge, version stamp, AKA line, audit date or variant marker. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion (lines 450-454) into the practice, the one supported claim, the evidence limitation and the borrowed-benefit caveat. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Counted programmatically: 57 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause traces to a distinct Conclusion passage: the breath pattern (line 450), the sleep-education comparison (line 450), the two studies and conflicted researcher (line 452), the borrowed benefits (line 454). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms or specialist classifications; the breath ratio is rendered as “short inhale, long hold, short exhale, silent phrase”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values; “two studies” is a count, not a citation. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes, relative risks or statistics; “beat sleep education” is directional only. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from the “Populations who should avoid Shabad Kriya” list inside the ER Key Interactions & Contraindications section (ER lines 291-299). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All seven ER avoid-list populations are represented, one-to-one and in ER order. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Each of the seven items is a discrete <li></li> inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing rationale stripped throughout: “where sustained breath retention is conventionally avoided”, “until pressure is controlled”, “where breath-hold-driven pressure changes are a concern” and “until the airway is treated” are all removed; no dash-introduced clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All parenthetical qualifiers preserved: (resting pressure ≥180/110 mmHg), (heart attack, <90 days), (chest pain at rest), (any seizure within the past 12 months), (15 or more breathing pauses per hour). |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER avoid-list uses no ranking notation inside parentheses; every parenthetical is a gloss or a numeric threshold. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is not empty, and the ER does identify populations that should avoid the practice, so the constraint holds. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no population that should avoid the intervention –> | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from the ten interaction bullets of the ER Key Interactions & Contraindications section (ER lines 271-289). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All ten ER interaction bullets are present, in ER order, and none duplicates a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each of the ten items is a discrete <li></li> inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every mechanism sentence and “Mitigation:” clause is stripped; the sedating-supplements item drops the ER content after the em-dash and retains only “Caution”. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists preserved in full for all seven drug-class items; only the ER plain-language glosses (“prescription sleeping pills:”, “blood-pressure drugs:”, “heart-slowing drugs:”, “common antidepressants:”, “steroid anti-inflammatories:”) and the Latin binomial for ashwagandha are trimmed for the one-page budget. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER interaction bullets use no ranking notation inside parentheses; every parenthetical is a gloss or an example drug list. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is not empty, and the ER does identify interactions that change how the practice is used, so the constraint holds. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no interaction that changes how the intervention is used –> | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from the ER Therapeutic Protocol section (ER lines 323-349). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Breath ratio, duration and timing relative to lights-out are the three defining execution variables; the ER itself names them as the equivalents of dosing (“session length, the hold-to-breath proportion, and proximity to lights-out”, ER line 339). The mantra placement is folded into action_1_sub. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section names far more than three actionable aspects, so all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields carry ER-derived content; action_1_sub reproduces the ER breath-ratio and mantra bullets, action_2_sub the duration bullet, action_3_sub the best-time-of-day bullet. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Onset over eight weeks (ER line 380), durability at six months (ER lines 161 and 354) and the eight-week decision point (ER line 316) are the three time-anchored findings in the ER. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered by magnitude of the related benefit: the primary sleep gain first, its six-month persistence second, and the stop/escalate point last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects, so all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time fields carry ER-derived content; time_1_sub is near-verbatim from ER line 380 and time_3_sub from ER line 316. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from the ER Expected Benefits section (ER lines 149-195). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four benefit variables are present in the Benefits card. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a bare restatement of the ER benefit headings; no effect sizes, magnitudes, attributions or mechanisms carried over, and the ER “Magnitude:” paragraphs are dropped entirely. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER benefit headings contain no parenthetical content, and none was introduced. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER records no High benefit (“No benefit reaches High”, ER line 155), and benefits_high carries style=”display: none” with no empty-state text. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from the ER Potential Risks & Side Effects section (ER lines 213-253). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four risk variables are present in the Risk & Side Effects card. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a bare restatement of the ER risk headings; the 8.3% prevalence figure, confidence interval and response-rate gap are all left out. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER risk headings contain no parenthetical content, and none was introduced. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER records no High risk (“No risk reaches High”, ER line 219), and risks_high carries style=”display: none” with no empty-state text. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success section (ER lines 404-420). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eleven rows of the ER biomarker table are reproduced, with names, optimal ranges and rationales matching the ER row for row. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | monitoring_cadence reproduces the ER baseline and follow-up schedule: two weeks of baseline, diary and Insomnia Severity Index at weeks 4 and 8, continuous wearable metrics, blood draw and blood pressure at 6 months then every 6-12 months (ER line 406). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the qualitative marker list in the ER Monitoring Protocol & Defining Success section (ER lines 424-430). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All seven ER qualitative markers are listed verbatim and in ER order. |
Issues 02/09/2026 01:34
Pass rate 100.00%. No issues found.